The risk and predictors for severe radiation pneumonitis in lung cancer patients treated with thoracic reirradiation
Open Access
- 16 April 2018
- journal article
- research article
- Published by Springer Nature in Radiation Oncology
- Vol. 13 (1) , 69
Abstract
Thoracic reirradiation (re-RT) is increasingly administered. However, radiation pneumonitis (RP) remains to be the most common side effect from retreatment. This study aimed to determine the risk and predictors for severe RP in patients receiving thoracic re-RT. Sixty seven patients with lung cancer received thoracic re-RT for recurrent or metastatic disease. Three-dimensional conformal radiotherapy (3D-CRT)/intensity modulated radiotherapy (IMRT) was used for 60 patients, and stereotactic body radiation therapy (SBRT) was used in 7 patients. Deformable image registration (DIR) was performed to create a composite plan. Severe (grade ≥ 3) RP was graded according to Common Terminology Criteria for Adverse Events version 4.0. Eighteen patients (26.9%) developed grade ≥ 3 RP (17 of grade 3, and 1 of grade 4). In univariate analyses, V5 and mean lung dose (MLD) of initial RT or re-RT plans, V5 and V20 of composite plans, and the overlap between V5 of initial RT and V5 of re-RT plans/V5 of re-RT plans (overlap-V5/re-V5) were significantly associated with grade ≥ 3 RP (P < 0.05 for each comparison). Multivariate analysis revealed that MLD of the initial RT plans (HR = 14.515, 95%CI:1.778–118.494, P = 0.013), V5 of the composite plans (HR = 7.398, 95%CI:1.319–41.495, P = 0.023), and overlap-V5/re-V5 (P = 0.041) were independent predictors for grade ≥ 3 RP. Out-of-field failures with medium overlap-V5/re-V5 of 0.4–0.8 was associated with higher risk of grade ≥ 3 RP compared with in-field failures (18.3% vs. 50%, P = 0.014). The risk of grade ≥ 3 RP could be predicted not only by dose-volume variables from re-RT plan, but also by some from initial-RT and composite plans. Out-of-field failures was associated with higher risk of severe RP compared with in-field failures in some cases.Keywords
This publication has 22 references indexed in Scilit:
- Stereotactic Body Radiation Therapy as Salvage for Intrathoracic Recurrence in Patients With Previously Irradiated Locally Advanced Non–Small Cell Lung CancerAmerican Journal of Clinical Oncology, 2016
- Available evidence on re-irradiation with stereotactic ablative radiotherapy following high-dose previous thoracic radiotherapy for lung malignanciesCancer Treatment Reviews, 2015
- Reirradiation for Locoregionally Recurrent Lung CancerAmerican Journal of Clinical Oncology, 2014
- Comparing rigid and deformable dose registration for high dose thoracic re-irradiationRadiotherapy and Oncology, 2013
- Stereotactic Body Radiation Therapy for Patients With Lung Cancer Previously Treated With Thoracic RadiationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Radiation Pulmonary Toxicity: From Mechanisms to ManagementSeminars in Radiation Oncology, 2010
- Definitive Chemoradiation for the Treatment of Locally Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2007
- Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: phase II trial.2004
- Three-dimensional conformal radiotherapy for locoregionally recurrent lung carcinoma after external beam irradiation: A prospective phase I–II clinical trialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2003
- Second‐line, low‐dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first‐line chemotherapy with carboplatin plus paclitaxelCancer, 2002